Journal of Crohn's & colitisHumansMaleFemaleAntibodiesMonoclonal
Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO study.
Fabio Salvatore Macaluso, Walter Fries, Anna Viola, Maria Cappello, Piera Melatti, Filippo Mocciaro, Barbara Scrivo, Simona Di Caro, Stefano Muscarella, Concetta Ferracane, Emiliano Giangreco, Maria Giovanna Minissale, Mauro Grova, Raffaele Li Voti, Giuseppe Mistretta
Published: 202510.1093/ecco-jcc/jjaf175
Abstract
BACKGROUND & AIMS: The optimal management of inflammatory bowel disease (IBD) patients with a partial response after intravenous (IV) vedolizumab (VDZ) induction remains unclear. METHODS: PRIVEDO was an observational, non-randomized, open-label, pros…
Preview only. Read the full abstract at the source